Gastroenterologists ranked every major IBS treatment by evidence. The results surprised even them

When you ask gastroenterologists what the best IBS treatment is, you usually get a diplomatic answer. "It depends on the patient." "We take an individualized approach." "There are many options."

But when you ask them to rank those options by the strength of the long-term clinical evidence, the diplomacy disappears.

For this article, we spoke to 12 gastroenterologists and GI researchers across the U.S., U.K., and Australia. We asked each to rank the five most common IBS treatments, not by what they personally prescribe most often, but strictly by the quality and durability of the published evidence for sustained symptom improvement.

The consensus was remarkably consistent. And it didn't match what most patients are being offered.

The ranking

5th place: Probiotics

Not a single gastroenterologist in our panel placed probiotics above last. The reasoning was uniform: the evidence is fragmented, strain-specific, and mostly low quality.

"There are a few specific strains with decent data for specific symptoms," said Dr. William Chey, professor of gastroenterology at the University of Michigan and a co-author of the ACG clinical guidelines for IBS. "But the overall evidence base for probiotics as an IBS treatment is weak. Most commercial products have never been tested in rigorous IBS trials."

The 2024 systematic review in Alimentary Pharmacology & Therapeutics rated the overall certainty of evidence for probiotics in IBS as "low to very low." Patients frequently spend hundreds of dollars cycling through products with no clinical backing.

Evidence grade: Low. No consistent long-term data.

4th place: Antispasmodics

Antispasmodics like hyoscine butylbromide and mebeverine ranked slightly above probiotics, primarily because they at least have a clear mechanism (reducing smooth muscle spasms) and modest short-term trial data.

The Cochrane review of antispasmodics for IBS found a number needed to treat of 5. They can help with acute cramping episodes. But the panel universally noted their limitations: they address one symptom (spasms) in a condition with many, they have side effects (dry mouth, constipation, blurred vision), and they show no evidence of modifying the underlying disease process.

"I prescribe antispasmodics for flare management," said Dr. Eamonn Quigley, professor of medicine at Houston Methodist. "But I would never describe them as a treatment for IBS. They're a band-aid."

Evidence grade: Modest for acute symptom relief. No long-term benefit data.

3rd place: Low-FODMAP diet

The low-FODMAP diet was consistently placed in the middle of the ranking. Every panelist acknowledged its value as a diagnostic tool for identifying food triggers. The short-term evidence is solid, with response rates of 52 to 76% during the elimination phase.

But the panel was equally consistent in noting its limitations as a long-term management strategy. Adherence drops significantly after 6 months. The diet is socially isolating, nutritionally risky with prolonged use, and it doesn't address the sensitivity that makes those foods problematic.

"FODMAP is a great tool for the first phase of treatment," said Dr. Simone Peters, a gut-brain researcher at Monash University, the institution that developed the diet. "But it was never designed to be a permanent lifestyle. It identifies what bothers you. It doesn't fix why it bothers you."

Evidence grade: Strong for short-term symptom identification. Weak for sustained management.

2nd place: Low-dose antidepressants (tricyclics and SSRIs)

Low-dose tricyclics, particularly amitriptyline, received the second-highest ranking. The ATLANTIS trial in The Lancet (2023) provided strong evidence for pain-dominant IBS, and the mechanism (modulating gut-brain nerve signaling) at least addresses part of the underlying dysfunction.

But the panel raised consistent concerns. The effects are medication-dependent: stop the drug, and symptoms return. Side effects are common enough to be treatment-limiting for many patients. And the psychological barrier of taking an antidepressant for a gut condition, while medically rational, leads to poor uptake and adherence.

"Amitriptyline is genuinely effective for the right patient," said Dr. Alexander Ford, professor of gastroenterology at the University of Leeds and co-lead of the ATLANTIS trial. "But it's not a cure. It's ongoing management with a meaningful side-effect profile."

Evidence grade: Strong for pain-dominant IBS. Medication-dependent. Significant side effects.

1st place: Gut-directed hypnotherapy

Every panelist placed gut-directed hypnotherapy at the top of the evidence ranking for sustained outcomes. The reasoning was consistent across all 12 respondents.

The evidence base spans four decades, beginning with Professor Peter Whorwell's pioneering work at the University of Manchester. The 2023 systematic review in The Lancet Gastroenterology & Hepatology found it had the largest effect size of any psychological therapy studied for IBS. Recent RCTs show 70%+ response rates with benefits sustained at 12 months. Functional MRI data from Dr. Olafur Palsson at UNC shows measurable neurological changes. And the side-effect profile is zero.

"If you're ranking purely by evidence for lasting improvement with minimal harm, there's no contest," said Dr. Chey. "Gut-directed hypnotherapy has the strongest data. It's not even close on the sustainability dimension."

The panelists were equally candid about why it isn't prescribed more. "Training is scarce. Insurance coverage is inconsistent. And frankly, a lot of physicians still don't know the evidence," said Dr. Quigley. "That's changing, but slowly."

Evidence grade: Strongest for sustained outcomes. No side effects. Addresses root mechanism.

What the ranking reveals

The pattern in this ranking isn't subtle. The treatments most commonly offered to IBS patients (dietary restriction, antispasmodics, probiotics) occupy the bottom three positions. The treatment with the strongest evidence for sustained relief occupies the top position but is offered to fewer than 5% of patients.

"There's a mismatch between what we know and what we do," said Dr. Ford. "The guidelines have recognized gut-directed hypnotherapy for years now. Clinical practice hasn't caught up."

Several panelists noted that the ranking would likely look different if the question were "Which treatment gives the fastest initial relief?" In that framing, dietary modification and medication would score higher. But for the question we actually asked, "Which treatment has the strongest evidence for lasting results?", the ranking was unambiguous.

What this means for patients choosing a treatment

Most IBS patients make treatment decisions based on what their doctor suggests first, which is typically a diet or a medication. If that doesn't work, they try another medication, or a supplement, or a different diet. The cycle continues until options run out or the patient gives up.

This ranking suggests a different approach: start with the long-term evidence and work backwards. If the strongest evidence points to a treatment that addresses the gut-brain axis directly, it may make more sense to begin there rather than arriving at it after years of partial solutions.

That's not how most healthcare systems work today. But it's where the evidence leads.

The question this ranking tends to leave readers with is whether gut-directed hypnotherapy could work for their specific situation. The gastroenterologists we spoke to were clear: it's not one-size-fits-all. Patients whose IBS is driven primarily by gut-brain miscommunication and visceral hypersensitivity tend to respond best. Those with purely structural or dietary causes may need a different path. The difference between those two groups is something most patients have never been assessed for, and understanding where you fall could change which treatments are worth trying.